"10.1371_journal.pone.0012702","plos one","2010-09-13T00:00:00Z","Hiromitsu Hatakeyama; Haixia Cheng; Pamela Wirth; Ashley Counsell; Samuel R Marcrom; Carey Burton Wood; Paula R Pohlmann; Jill Gilbert; Barbara Murphy; Wendell G Yarbrough; Deric L Wheeler; Paul M Harari; Yan Guo; Yu Shyr; Robbert J Slebos; Christine H Chung","Division of Hematology/Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Otolaryngology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America; Department of Biostatistics, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America","Conceived and designed the experiments: HH CHC. Performed the experiments: HH HC PW AC SRM CBW. Analyzed the data: HH YG YS RJS CHC. Contributed reagents/materials/analysis tools: PRP JG BM WGY DLW PH CHC. Wrote the paper: HH RJS CHC.","CHC received honoraria from Bristol-Myers Squibb for providing educational lectures and serving on a scientific advisory board. DLW holds a sponsored research agreement with Bristol-Myers Squibb. PMH has held laboratory research agreements with industry sponsors developing EGFR inhibitors including Amgen, AstraZeneca, Genentech and ImClone. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2010","09","Hiromitsu Hatakeyama","HH",16,TRUE,2,6,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
